NorthStar And PDRadiopharma Partner To Revolutionize Radiopharmaceuticals For Cancer Treatment

NorthStar Medical Radioisotopes, LLC, and PeptiDream Inc. announced a strategic collaboration between NorthStar and PeptiDream’s subsidiary, PDRadiopharma Inc., a leading radiopharmaceutical company in Japan. PDRadiopharma has over 50 years of expertise in providing high-quality radiodiagnostic agents for SPECT and PET imaging and is now focused on advancing next-generation targeted radiodiagnostics and radiotherapeutics to improve the diagnosis and treatment of various cancers.

Masato Murakami, President and Representative Director at PDRadiopharma and Chief Medical Officer at PeptiDream, said in a statement, “Through this alliance, we aim to utilise NorthStar’s cutting-edge innovative technologies and expertise to both support and accelerate our growing internal pipeline of targeted peptide-RI conjugate programs, initially starting with our exciting CA9 program.”

He also stated, “Since being acquired by PeptiDream in 2022, we have been working to combine PeptiDream’s world-leading drug discovery technology and capabilities with PDRadiopharma’s expertise in radiopharmaceutical development, manufacturing, and commercialisation to develop novel radiotherapeutic treatments for cancer patients where the unmet need is high. Our agreements with NorthStar for research and development services, supply of the isotope Ac-225 and contract manufacturing services will be an important part of our efforts to bring new medicines to patients who need them and our commitment to stable, reliable product supply.” 

PeptiDream is committed to revolutionising drug discovery and creating innovative medicines to transform global healthcare. Since its founding in 1968, PDRadiopharma has been at the forefront of radiopharmaceutical innovation, delivering diagnostics and therapies for conditions such as brain, heart, and bone diseases and cancer.

Frank Scholz, President and Chief Executive Officer of NorthStar, commented, “At NorthStar, our passion is to reduce technological and operational barriers to help companies like PeptiDream and PDRadiopharma develop and reliably manufacture finished, patient-ready drug products for investigators and clinical trials and continue to explore novel therapies for the patients who need new and better medicines. PeptiDream is a global leader in the discovery of targeting peptide-based radioligands. It partners with some of the largest, best-known pharmaceutical and biotech companies in these efforts with cutting edge science and deep portfolios and through its wholly-owned subsidiary PDRadiopharma. It is developing a growing pipeline of internal programs, including the company’s promising CA9 program. NorthStar is proud to be supporting PeptiDream and PDRadiopharma to help make new diagnostics and therapeutic medicines a reality for today’s patients.“ 

As part of this collaboration, NorthStar will be responsible for the following:

1. Provide research and development (R&D) services for PDRadiopharma’s lead therapeutic asset, 225Ac-CA9 (225Ac-PD-32766).

2. Use its state-of-the-art development and manufacturing facility to supply Actinium-225 (Ac225) and produce patient doses of novel diagnostic and therapeutic agents for PDRadiopharma’s clinical trials.

3. Conduct R&D activities to support the continued growth and advancement of PDRadiopharma’s portfolio of assets.

This partnership aims to accelerate the development of innovative radiopharmaceuticals, benefiting patients worldwide.